TOP STORIES

• BUSINESS Kobayashi Kako Recalls 12 More APIs after On-Site Inspections
  December 25, 2020

• BUSINESS Daiichi Sankyo Espha Stops Supply of 3 APIs after Kobayashi Kako Mix-up
  December 25, 2020

• BUSINESS 49 APIs Listed in 2020, 10 Billion-Plus Yen Peak Sales Projected for 17: Jiho Tally
  December 24, 2020

• ACADEMIA Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
  December 24, 2020

• REGULATORY Results of On-Site Probe into Kobayashi Kako Due Out Early Next Year, MHLW Eyes Biz Suspension
  December 24, 2020

• BUSINESS Axcelead Looks to Unearth New Drugs from Takeda’s Legacy Assets, 5-Plus Collaborations Ongoing
  December 23, 2020

• BUSINESS Meiji, Again, Halts Supply of Kobayashi Kako-Made Drugs after On-Site Inspections
  December 23, 2020

• REGULATORY Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
  December 22, 2020

• ORGANIZATION 3 Indicted Wholesalers Now Barred from National Hospital Organization Bids, Others Following Suit
  December 21, 2020

• REGULATORY Japan Saves 431.5 Billion Yen in Drug Price Cuts, Curbs Social Security Costs: FY2021 Draft Budget
  December 21, 2020

• BUSINESS Decision on Pfizer Vaccine Unlikely to Come before Japan Data Submission Slated by February
  December 21, 2020

• BUSINESS Pfizer/BioNTech’s COVID-19 Vaccine Filed in Japan, Exceptional OK Eyed
  December 18, 2020

• BUSINESS 5%-Plus Discrepancy Threshold for Off-Year Re-Pricing Draws Fire from Pharma, Wholesalers
  December 18, 2020

• REGULATORY Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
  December 18, 2020

• REGULATORY Govt Settles on Discrepancy Rate Threshold of “Above 5%” for Off-Year Drug Re-Pricing, 430 Billion Yen Reduction, 60% Coverage for Innovative Meds
  December 17, 2020

• REGULATORY Japan Govt Eyes 4-6% Price Discrepancy Threshold for Off-Year Drug Re-Pricing
  December 16, 2020

• BUSINESS UCB Japan to Independently Market New Products; Stand-Alone E Keppra Sales “Going Smoothly”: President
  December 16, 2020

• REGULATORY Japan Weighs Drug Cost Cut of around 400 Billion Yen in Off-Year Re-Pricing, Expanded Coverage Including Products with Smaller-than-Average Price Gap Too
  December 15, 2020

• BUSINESS Forxiga Filed for Chronic Kidney Disease in Japan: AZ
  December 15, 2020

• BUSINESS 1st Death Reported for Kobayashi Kako’s Tainted Itraconazole Product
  December 14, 2020

ページ

• « 先頭
• ‹ Prev
• …
• 102
• 103
• 104
• 105
• 106
• 107
• 108
• 109
• 110
• …
• Next ›
• 最終 »